Journal
JOURNAL OF CHEMICAL INFORMATION AND MODELING
Volume 63, Issue 4, Pages 1301-1312Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jcim.2c01586
Keywords
-
Ask authors/readers for more resources
Targeted covalent inhibitors show potential for drug discovery, specifically for kinases. Targeting the catalytic lysine of EGFR has gained attention for overcoming resistance caused by the C797S mutation. Sulfonyl fluoride derivatives have been reported as inhibitors of EGFRL858R/T790M/C797S through sulfonylation of Lys745. However, the mechanism behind this process is poorly understood.
Targeted covalent inhibitors hold promise for drug discovery, particularly for kinases. Targeting the catalytic lysine of epidermal growth factor receptor (EGFR) has attracted attention as a new strategy to overcome resistance due to the emergence of C797S mutation. Sulfonyl fluoride derivatives able to inhibit EGFRL858R/T790M/C797S by sulfonylation of Lys745 have been reported. However, atomistic details of this process are still poorly understood. Here, we describe the mechanism of inhibition of an innovative class of compounds that covalently engage the catalytic lysine of EGFR, through a sulfur(VI) fluoride exchange (SuFEx) process, with the help of hybrid quantum mechanics/molecular mechanics (QM/MM) and path collective variables (PCVs) approaches. Our simulations identify the chemical determinants accounting for the irreversible activity of agents targeting Lys745 and provide hints for the further optimization of sulfonyl fluoride agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available